Immunome (IMNM) Stock Forecast & Price Target

Compare

322 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMNM Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Immunome

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMNM Stock 12 Month Forecast

Average Price Target

$22.38

▲(118.34% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Immunome in the last 3 months. The average price target is $22.38 with a high forecast of $38.00 and a low forecast of $10.00. The average price target represents a 118.34% change from the last price of $10.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","22":"$22","39":"$39","13.5":"$13.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,13.5,22,30.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.59,12.698461538461538,14.806923076923077,16.915384615384617,19.023846153846154,21.13230769230769,23.24076923076923,25.349230769230772,27.45769230769231,29.56615384615385,31.674615384615386,33.78307692307692,35.89153846153846,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.59,11.496923076923077,12.403846153846153,13.31076923076923,14.217692307692307,15.124615384615385,16.03153846153846,16.93846153846154,17.845384615384614,18.752307692307692,19.659230769230767,20.566153846153846,21.473076923076924,{"y":22.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.59,10.544615384615385,10.499230769230769,10.453846153846154,10.408461538461538,10.363076923076923,10.317692307692308,10.272307692307692,10.226923076923077,10.181538461538462,10.136153846153846,10.090769230769231,10.045384615384615,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.69,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.18,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.52,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.59,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$38.00

Average Price Target$22.38

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dex Genotek

TR | OpenAI - 4o

$10

Hold

-2.44%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Andrew Berens

Leerink Partners

$38

Buy

270.73%

Upside

Reiterated

08/07/25

Immunome's Promising Pipeline and Financial Stability Justify Buy Rating

Biren Amin

Piper Sandler

$21

Buy

104.88%

Upside

Reiterated

08/07/25

Piper Sandler Sticks to Their Buy Rating for Immunome (IMNM)

Chad Messer

Lake Street

$23→$22

Buy

114.63%

Upside

Reiterated

08/07/25

Immunome (IMNM) Receives a Buy from Lake Street

Brian Cheng

J.P. Morgan

$23→$22

Buy

114.63%

Upside

Reiterated

08/07/25

J.P. Morgan Keeps Their Buy Rating on Immunome (IMNM)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$21

Buy

104.88%

Upside

Reiterated

08/07/25

Wedbush Keeps Their Buy Rating on Immunome (IMNM)

Charles Zhu

LifeSci Capital

$20

Buy

95.12%

Upside

Initiated

08/06/25

Immunome's Promising Clinical Progress and Strong Financial Position Justify Buy Rating

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/06/25

Promising Outlook for Immunome's Varegacestat: Buy Rating Affirmed

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$25

Buy

143.90%

Upside

Reiterated

08/06/25

Guggenheim Reaffirms Their Buy Rating on Immunome (IMNM)

Jason Kolbert

D. Boral Capital

―

Hold

―

Downgraded

05/19/25

D. Boral Capital downgrades Immunome Inc. (IMNM) to Hold Pending Financial ClarityD. Boral Capital analyst Jason Kolbert downgraded Immunome Inc. (NASDAQ: IMNM) from Buy to Hold.

Sudan Loganathan

Stephens

$30

Buy

192.68%

Upside

Initiated

11/07/24

Immunome initiated with an Overweight at StephensImmunome initiated with an Overweight at Stephens

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dex Genotek

TR | OpenAI - 4o

$10

Hold

-2.44%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Andrew Berens

Leerink Partners

$38

Buy

270.73%

Upside

Reiterated

08/07/25

Immunome's Promising Pipeline and Financial Stability Justify Buy Rating

Biren Amin

Piper Sandler

$21

Buy

104.88%

Upside

Reiterated

08/07/25

Piper Sandler Sticks to Their Buy Rating for Immunome (IMNM)

Chad Messer

Lake Street

$23→$22

Buy

114.63%

Upside

Reiterated

08/07/25

Immunome (IMNM) Receives a Buy from Lake Street

Brian Cheng

J.P. Morgan

$23→$22

Buy

114.63%

Upside

Reiterated

08/07/25

J.P. Morgan Keeps Their Buy Rating on Immunome (IMNM)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$21

Buy

104.88%

Upside

Reiterated

08/07/25

Wedbush Keeps Their Buy Rating on Immunome (IMNM)

Charles Zhu

LifeSci Capital

$20

Buy

95.12%

Upside

Initiated

08/06/25

Immunome's Promising Clinical Progress and Strong Financial Position Justify Buy Rating

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/06/25

Promising Outlook for Immunome's Varegacestat: Buy Rating Affirmed

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$25

Buy

143.90%

Upside

Reiterated

08/06/25

Guggenheim Reaffirms Their Buy Rating on Immunome (IMNM)

Jason Kolbert

D. Boral Capital

―

Hold

―

Downgraded

05/19/25

D. Boral Capital downgrades Immunome Inc. (IMNM) to Hold Pending Financial ClarityD. Boral Capital analyst Jason Kolbert downgraded Immunome Inc. (NASDAQ: IMNM) from Buy to Hold.

Sudan Loganathan

Stephens

$30

Buy

192.68%

Upside

Initiated

11/07/24

Immunome initiated with an Overweight at StephensImmunome initiated with an Overweight at Stephens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunome

1 Month

xxx

Success Rate

7/10 ratings generated profit

Average Return

+0.19%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +0.19% per trade.

3 Months

xxx

Success Rate

5/7 ratings generated profit

Average Return

+3.37%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +3.37% per trade.

1 Year

Biren AminPiper Sandler

Success Rate

4/7 ratings generated profit

Average Return

-2.20%

reiterated a buy rating 13 days ago

Copying Biren Amin's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -2.20% per trade.

2 Years

xxx

Success Rate

3/5 ratings generated profit

Average Return

-15.98%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of -15.98% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMNM Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMNM has received 11 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. IMNM average Analyst price target in the past 3 months is 22.38.

Each month's total comprises the sum of three months' worth of ratings.

IMNM Financial Forecast

IMNM Earnings Forecast

Next quarter’s earnings estimate for IMNM is -$0.55 with a range of -$0.63 to -$0.46. The previous quarter’s EPS was -$0.50. IMNM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year IMNM has Preformed in-line its overall industry.

IMNM Sales Forecast

Next quarter’s sales forecast for IMNM is $143.00K with a range of $0.00 to $1.00M. The previous quarter’s sales results were $4.01M. IMNM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.26% of the time in the same period. In the last calendar year IMNM has Preformed in-line its overall industry.

IMNM Stock Forecast FAQ

What is IMNM’s average 12-month price target, according to analysts?

Based on analyst ratings, Immunome’s 12-month average price target is 22.38.

What is IMNM’s upside potential, based on the analysts’ average price target?

Immunome has 118.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMNM a Buy, Sell or Hold?

Immunome has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Immunome’s price target?

The average price target for Immunome is 22.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $38.00 ,the lowest forecast is $10.00. The average price target represents 118.34% Increase from the current price of $10.25.

What do analysts say about Immunome?

Immunome’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of IMNM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Immunome (IMNM) Stock Forecast & Price Target

IMNM Analyst Ratings

IMNM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Immunome

IMNM Analyst Recommendation Trends

IMNM Financial Forecast

IMNM Earnings Forecast

IMNM Sales Forecast

IMNM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts